 <h1>Aldesleukin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of aldesleukin include:</b> supraventricular tachycardia, acute respiratory distress syndrome, congestive heart failure, exfoliative dermatitis, infection, pulmonary congestion, pulmonary infiltrates, respiratory system disorder, cardiac arrhythmia, drowsiness, edema, abdominal pain, acidosis, altered blood pressure, anemia, anxiety, asthenia, asymptomatic ecg changes, cardiovascular disorder, confusion, diarrhea, dizziness, dyspnea, enlargement of abdomen, fever, hyperbilirubinemia, hypocalcemia, hypomagnesemia, hypotension, increased cough, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum creatinine, leukopenia, nausea, oliguria, pain, peripheral edema, pruritus, pulmonary disease, rales, rhinitis, rhonchi, skin rash, stomatitis, tachycardia, thrombocytopenia, vasodilation, vomiting, weight gain, anorexia, chills, and malaise.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to aldesleukin: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Therapy should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Administration has been associated with capillary leak syndrome, which may be severe and can result in death. Treatment is also associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Administration should be withheld in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, aldesleukin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking aldesleukin:</p><p>
<i>More common</i>
</p><ul>
<li>Agitation</li>
<li>confusion</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>fever or chills</li>
<li>mental depression</li>
<li>nausea and vomiting</li>
<li>shortness of breath</li>
<li>sores in the mouth and on lips</li>
<li>tingling of the hands or feet</li>
<li>unusual decrease in urination</li>
<li>unusual tiredness or weakness</li>
<li>weight gain of 5 to 10 pounds or more</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bloating and stomach pain</li>
<li>blurred or double vision</li>
<li>faintness</li>
<li>fast or irregular heartbeat</li>
<li>loss of taste</li>
<li>rapid breathing</li>
<li>redness, swelling, and soreness of the tongue</li>
<li>trouble with speaking</li>
<li>yellow eyes and skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Changes in menstrual periods</li>
<li>clumsiness</li>
<li>coldness</li>
<li>convulsions (seizures)</li>
<li>listlessness</li>
<li>muscle aches</li>
<li>pain or redness at injection site</li>
<li>sudden inability to move</li>
<li>swelling in the front of the neck</li>
<li>swelling of the feet or lower legs</li>
<li>weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blisters on the skin</li>
<li>blood in the urine</li>
<li>bloody vomit</li>
<li>chest pain</li>
<li>cough or hoarseness</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pinpoint red spots on the skin</li>
<li>stomach pain (severe)</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of aldesleukin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Dry skin</li>
<li>loss of appetite</li>
<li>skin rash or redness with burning or itching, followed by peeling</li>
<li>unusual feeling of discomfort or illness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Constipation</li>
<li>headache</li>
<li>joint pain</li>
<li>muscle pain</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to aldesleukin: intravenous powder for injection</i></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-aldesleukin antibodies (74%)</p>
<p><b>Common</b> (1% to 10%): Neutralizing antibodies<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (71%), tachycardia (23%), vasodilation (13%), supraventricular tachycardia (12%), cardiovascular disorder (11%), arrhythmia (10%), chest pain</p>
<p><b>Common</b> (1% to 10%): Myocardial infarction, ventricular tachycardia, cardiac arrest, cyanosis, transient ECG changes, myocardial ischemia, palpitations, phlebitis, hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): Hemorrhage (including subdural, subarachnoid, cerebral, retroperitoneal), myocarditis, cardiomyopathy, pericardial effusion, thrombosis, thrombophlebitis</p>
<p><b>Rare</b> (less than 0.1%): Ventricular hypokinesia</p>
<p><b>Frequency not reported</b>: Capillary leak syndrome (CLS), hypoperfusion, bradycardia, ventricular extrasystoles, atrial arrhythmia, second degree AV block, endocarditis, coronary artery disorder, transient ischemic attacks, pericarditis, shock</p>
<p><b>Postmarketing reports</b>: Cardiac tamponade<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (67%), vomiting (50%), nausea (35%), stomatitis (22%), nausea with vomiting (19%), abdominal pain (11%), enlarged abdomen (10%)</p>
<p><b>Common</b> (1% to 10%): Dysphagia, dyspepsia, constipation, GI bleeding (including rectal hemorrhage), hematemesis, ascites, cheilitis, gastritis</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, intestinal obstruction, GI perforation (including necrosis/gangrene)</p>
<p><b>Rare</b> (less than 0.1%): Activation of quiescent Crohn's disease</p>
<p><b>Frequency not reported</b>: GI hemorrhage, bloody diarrhea, GI disorder, intestinal perforation, duodenal ulceration, bowel necrosis, bowel perforation/infarction</p>
<p><b>Postmarketing reports</b>: Colitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Oliguria (63%), increased serum creatinine (33%), increased serum urea</p>
<p><b>Common</b> (1% to 10%): Anuria, hematuria, renal failure</p>
<p><b>Frequency not reported</b>: Increased blood urea nitrogen, crescentic IgA glomerulonephritis, acute tubular necrosis, allergic interstitial nephritis</p>
<p><b>Postmarketing reports</b>: Increased hyperuricemia non-protein nitrogen<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Chills (52%), fever (29%), peripheral edema (28%), malaise (27%), asthenia/fatigue (23%), edema (15%), infection (13%), pain (12%), injection site reactions, injection site necrosis, injection site pain, injection site inflammation</p>
<p><b>Common</b> (1% to 10%): Sepsis, mucositis, injection site nodule, hypothermia</p>
<p><b>Frequency not reported</b>: Peripheral gangrene, atypical reactions to iodinated contrast media, catheter site infections, bacterial infections, malignant hyperthermia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (43%), lung disorder (24%), respiratory disorder (11%), increased cough (11%), rhinitis (10%)</p>
<p><b>Common</b> (1% to 10%): Apnea, respiratory tract infection, lung/pulmonary edema, pleural effusion, hypoxia, hemoptysis, epistaxis, nasal congestion, rhinitis</p>
<p><b>Rare</b> (less than 0.1%): Pulmonary embolism</p>
<p><b>Frequency not reported</b>: Respiratory acidosis, asthma, hyperventilation, hypoventilation, pneumothorax, trachea-esophageal fistula, respiratory arrest</p>
<p><b>Postmarketing reports</b>: Pneumonia (bacterial, fungal, viral)<sup>[Ref]</sup></p><p>Lung disorder includes physical findings associated with pulmonary congestion, rales, and rhonchi.  Respiratory disorder includes acute respiratory distress syndrome (ARDS), chest x-ray infiltrates, respiratory failure, intubation, and unspecified pulmonary changes.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Erythema and rash (42%), pruritus (24%), exfoliative dermatitis (18%), sweating</p>
<p><b>Common</b> (1% to 10%): Urticaria, alopecia</p>
<p><b>Uncommon</b> (0.1% to 1%): Quincke's edema, vitiligo</p>
<p><b>Rare</b> (less than 0.1%): Vesiculobullous rash, Stevens-Johnson syndrome</p>
<p><b>Frequency not reported</b>: Bullous pemphigoid, cutaneous and leukocytoclastic hypersensitivity vasculitis</p>
<p><b>Postmarketing reports</b>: Cellulitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Bilirubinemia (40%), increased SGOT (23%) </p>
<p><b>Common</b> (1% to 10%): Acute kidney failure, elevation of hepatic transaminases</p>
<p><b>Uncommon</b> (0.1% to 1%): Hyperbilirubinemia, hepatomegaly/hepatosplenomegaly</p>
<p><b>Rare</b> (less than 0.1%): Cholecystitis, liver failure</p>
<p><b>Frequency not reported</b>: Abnormal liver function tests, abnormal kidney function</p>
<p><b>Postmarketing reports</b>: Hepatitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (37%), anemia (29%), leukopenia (16%)</p>
<p><b>Common</b> (1% to 10%): Coagulopathy (including disseminated intravascular coagulation), eosinophilia </p>
<p><b>Uncommon</b> (0.1% to 1%): Neutropenia</p>
<p><b>Rare</b> (less than 0.1%): Agranulocytosis, aplastic anemia, hemolytic anemia, neutropenic fever</p>
<p><b>Frequency not reported</b>: Leukocytosis, lymphocytosis</p>
<p><b>Postmarketing reports</b>: Lymphocytopenia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Confusion (34%), anxiety (12%), depression, insomnia</p>
<p><b>Common</b> (1% to 10%): Psychosis, irritability, agitation, hallucinations</p>
<p><b>Frequency not reported</b>: Paranoid reaction, delirium, suicide<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Hypothyroidism</p>
<p><b>Common</b> (1% to 10%): Hyperthyroidism, hyperglycemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypoglycemia</p>
<p><b>Rare</b> (less than 0.1%): Diabetes mellitus</p>
<p><b>Frequency not reported</b>: Thyroiditis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (20%), weight gain (16%), acidosis (12%), hypomagnesemia (12%), hypocalcemia (11%), increased alkaline phosphatase (10%), weight loss</p>
<p><b>Common</b> (1% to 10%): Hypercalcemia, hyperkalemia, dehydration, elevated lactic dehydrogenase<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Somnolence (22%), dizziness (11%), headache, paresthesia</p>
<p><b>Common</b> (1% to 10%): Coma, stupor, neuropathy, syncope, speech disorders, taste loss, lethargy</p>
<p><b>Uncommon</b> (0.1% to 1%): Convulsions, paralysis</p>
<p><b>Rare</b> (less than 0.1%): Leukoencephalopathy</p>
<p><b>Frequency not reported</b>: Grand mal convulsion, meningitis, cerebral edema, mental status changes, ataxia (limb or gait), cortical lesion, cerebral vasculitis, obtundation, cerebrovascular accident, stroke, cerebral vasculitis</p>
<p><b>Postmarketing reports</b>: Cerebral lesions, extrapyramidal syndrome, neuralgia, neuritis, demyelinating neuropathy<sup>[Ref]</sup></p><h3>General</h3><p>Most adverse reactions were self-limited and usually reversed or improved within 1 to 3 days of therapy cessation; however, some adverse reactions (e.g., myocardial infarction, bowl perforation/infarction, gangrene) have permanent sequelae.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions</p>
<p><b>Rare</b> (less than 0.1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia, arthralgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Myasthenia, myopathy, myositis</p>
<p><b>Frequency not reported</b>: Scleroderma, inflammatory arthritis, oculobulbar myasthenia gravis</p>
<p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis</p>
<p><b>Rare</b> (less than 0.1%): Optic nerve disorder (including optic neuritis)</p>
<p><b>Frequency not reported</b>: Cortical blindness, mydriasis, pupillary disorder, blindness (permanent and transient)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about aldesleukin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: interleukins</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Aldesleukin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Proleukin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Melanoma</li>
<li>Melanoma, Metastatic</li>
<li>Renal Cell Carcinoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to aldesleukin: intravenous powder for injection</i></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-aldesleukin antibodies (74%)</p><p><b>Common</b> (1% to 10%): Neutralizing antibodies<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (71%), tachycardia (23%), vasodilation (13%), supraventricular tachycardia (12%), cardiovascular disorder (11%), arrhythmia (10%), chest pain</p><p><b>Common</b> (1% to 10%): Myocardial infarction, ventricular tachycardia, cardiac arrest, cyanosis, transient ECG changes, myocardial ischemia, palpitations, phlebitis, hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Hemorrhage (including subdural, subarachnoid, cerebral, retroperitoneal), myocarditis, cardiomyopathy, pericardial effusion, thrombosis, thrombophlebitis</p><p><b>Rare</b> (less than 0.1%): Ventricular hypokinesia</p><p><b>Frequency not reported</b>: Capillary leak syndrome (CLS), hypoperfusion, bradycardia, ventricular extrasystoles, atrial arrhythmia, second degree AV block, endocarditis, coronary artery disorder, transient ischemic attacks, pericarditis, shock</p><p><b>Postmarketing reports</b>: Cardiac tamponade<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (67%), vomiting (50%), nausea (35%), stomatitis (22%), nausea with vomiting (19%), abdominal pain (11%), enlarged abdomen (10%)</p><p><b>Common</b> (1% to 10%): Dysphagia, dyspepsia, constipation, GI bleeding (including rectal hemorrhage), hematemesis, ascites, cheilitis, gastritis</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, intestinal obstruction, GI perforation (including necrosis/gangrene)</p><p><b>Rare</b> (less than 0.1%): Activation of quiescent Crohn's disease</p><p><b>Frequency not reported</b>: GI hemorrhage, bloody diarrhea, GI disorder, intestinal perforation, duodenal ulceration, bowel necrosis, bowel perforation/infarction</p><p><b>Postmarketing reports</b>: Colitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Oliguria (63%), increased serum creatinine (33%), increased serum urea</p><p><b>Common</b> (1% to 10%): Anuria, hematuria, renal failure</p><p><b>Frequency not reported</b>: Increased blood urea nitrogen, crescentic IgA glomerulonephritis, acute tubular necrosis, allergic interstitial nephritis</p><p><b>Postmarketing reports</b>: Increased hyperuricemia non-protein nitrogen<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Chills (52%), fever (29%), peripheral edema (28%), malaise (27%), asthenia/fatigue (23%), edema (15%), infection (13%), pain (12%), injection site reactions, injection site necrosis, injection site pain, injection site inflammation</p><p><b>Common</b> (1% to 10%): Sepsis, mucositis, injection site nodule, hypothermia</p><p><b>Frequency not reported</b>: Peripheral gangrene, atypical reactions to iodinated contrast media, catheter site infections, bacterial infections, malignant hyperthermia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (43%), lung disorder (24%), respiratory disorder (11%), increased cough (11%), rhinitis (10%)</p><p><b>Common</b> (1% to 10%): Apnea, respiratory tract infection, lung/pulmonary edema, pleural effusion, hypoxia, hemoptysis, epistaxis, nasal congestion, rhinitis</p><p><b>Rare</b> (less than 0.1%): Pulmonary embolism</p><p><b>Frequency not reported</b>: Respiratory acidosis, asthma, hyperventilation, hypoventilation, pneumothorax, trachea-esophageal fistula, respiratory arrest</p><p><b>Postmarketing reports</b>: Pneumonia (bacterial, fungal, viral)<sup>[Ref]</sup></p><p>Lung disorder includes physical findings associated with pulmonary congestion, rales, and rhonchi.  Respiratory disorder includes acute respiratory distress syndrome (ARDS), chest x-ray infiltrates, respiratory failure, intubation, and unspecified pulmonary changes.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Erythema and rash (42%), pruritus (24%), exfoliative dermatitis (18%), sweating</p><p><b>Common</b> (1% to 10%): Urticaria, alopecia</p><p><b>Uncommon</b> (0.1% to 1%): Quincke's edema, vitiligo</p><p><b>Rare</b> (less than 0.1%): Vesiculobullous rash, Stevens-Johnson syndrome</p><p><b>Frequency not reported</b>: Bullous pemphigoid, cutaneous and leukocytoclastic hypersensitivity vasculitis</p><p><b>Postmarketing reports</b>: Cellulitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Bilirubinemia (40%), increased SGOT (23%) </p><p><b>Common</b> (1% to 10%): Acute kidney failure, elevation of hepatic transaminases</p><p><b>Uncommon</b> (0.1% to 1%): Hyperbilirubinemia, hepatomegaly/hepatosplenomegaly</p><p><b>Rare</b> (less than 0.1%): Cholecystitis, liver failure</p><p><b>Frequency not reported</b>: Abnormal liver function tests, abnormal kidney function</p><p><b>Postmarketing reports</b>: Hepatitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (37%), anemia (29%), leukopenia (16%)</p><p><b>Common</b> (1% to 10%): Coagulopathy (including disseminated intravascular coagulation), eosinophilia </p><p><b>Uncommon</b> (0.1% to 1%): Neutropenia</p><p><b>Rare</b> (less than 0.1%): Agranulocytosis, aplastic anemia, hemolytic anemia, neutropenic fever</p><p><b>Frequency not reported</b>: Leukocytosis, lymphocytosis</p><p><b>Postmarketing reports</b>: Lymphocytopenia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Confusion (34%), anxiety (12%), depression, insomnia</p><p><b>Common</b> (1% to 10%): Psychosis, irritability, agitation, hallucinations</p><p><b>Frequency not reported</b>: Paranoid reaction, delirium, suicide<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Hypothyroidism</p><p><b>Common</b> (1% to 10%): Hyperthyroidism, hyperglycemia</p><p><b>Uncommon</b> (0.1% to 1%): Hypoglycemia</p><p><b>Rare</b> (less than 0.1%): Diabetes mellitus</p><p><b>Frequency not reported</b>: Thyroiditis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (20%), weight gain (16%), acidosis (12%), hypomagnesemia (12%), hypocalcemia (11%), increased alkaline phosphatase (10%), weight loss</p><p><b>Common</b> (1% to 10%): Hypercalcemia, hyperkalemia, dehydration, elevated lactic dehydrogenase<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Somnolence (22%), dizziness (11%), headache, paresthesia</p><p><b>Common</b> (1% to 10%): Coma, stupor, neuropathy, syncope, speech disorders, taste loss, lethargy</p><p><b>Uncommon</b> (0.1% to 1%): Convulsions, paralysis</p><p><b>Rare</b> (less than 0.1%): Leukoencephalopathy</p><p><b>Frequency not reported</b>: Grand mal convulsion, meningitis, cerebral edema, mental status changes, ataxia (limb or gait), cortical lesion, cerebral vasculitis, obtundation, cerebrovascular accident, stroke, cerebral vasculitis</p><p><b>Postmarketing reports</b>: Cerebral lesions, extrapyramidal syndrome, neuralgia, neuritis, demyelinating neuropathy<sup>[Ref]</sup></p><h3>General</h3><p>Most adverse reactions were self-limited and usually reversed or improved within 1 to 3 days of therapy cessation; however, some adverse reactions (e.g., myocardial infarction, bowl perforation/infarction, gangrene) have permanent sequelae.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions</p><p><b>Rare</b> (less than 0.1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia, arthralgia</p><p><b>Uncommon</b> (0.1% to 1%): Myasthenia, myopathy, myositis</p><p><b>Frequency not reported</b>: Scleroderma, inflammatory arthritis, oculobulbar myasthenia gravis</p><p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis</p><p><b>Rare</b> (less than 0.1%): Optic nerve disorder (including optic neuritis)</p><p><b>Frequency not reported</b>: Cortical blindness, mydriasis, pupillary disorder, blindness (permanent and transient)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics, Emeryville, CA. </p><h2>More about aldesleukin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: interleukins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Aldesleukin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Melanoma</li>
<li>Melanoma, Metastatic</li>
<li>Renal Cell Carcinoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>